Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Non-Current Assets: 2011-2025

Historic Non-Current Assets for Abeona Therapeutics (ABEO) over the last 15 years, with Sep 2025 value amounting to $15.0 million.

  • Abeona Therapeutics' Non-Current Assets rose 88.59% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 88.59%. This contributed to the annual value of $8.1 million for FY2024, which is 2.26% down from last year.
  • Abeona Therapeutics' Non-Current Assets amounted to $15.0 million in Q3 2025, which was up 7.11% from $14.0 million recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' Non-Current Assets peaked at $52.8 million during Q1 2021, and registered a low of $7.9 million during Q3 2024.
  • Over the past 3 years, Abeona Therapeutics' median Non-Current Assets value was $8.8 million (recorded in 2023), while the average stood at $10.0 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first plummeted by 74.05% in 2022, then soared by 88.59% in 2025.
  • Over the past 5 years, Abeona Therapeutics' Non-Current Assets (Quarterly) stood at $23.3 million in 2021, then tumbled by 52.28% to $11.1 million in 2022, then declined by 25.64% to $8.3 million in 2023, then fell by 2.26% to $8.1 million in 2024, then soared by 88.59% to $15.0 million in 2025.
  • Its Non-Current Assets stands at $15.0 million for Q3 2025, versus $14.0 million for Q2 2025 and $11.2 million for Q1 2025.